Amr A Heikal

Dr. Amr A Heikal

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2022 in Brachytherapy
Verified
Journal Article
Closed access
GMGeetha Menon
Geetha Menon
LBLesley Baldwin
Lesley Baldwin
AHAmr A Heikal
Amr A Heikal
BBBen Burke
Ben Burke

4 October 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
AWASMARA WAHEED
ASMARA WAHEED
SMShannah Murland
Shannah Murland
EYEugene Yip
Eugene Yip
AHAmr A Heikal
Amr A Heikal
SGSunita Ghosh
Sunita Ghosh
KJKurian Joseph
Kurian Joseph
Background: Stereotactic body radiotherapy (SBRT) is an evolving treatment for the local management of pancreatic cancer (PC). The main purpose of this study is to report our initial experience in terms of local control (LC) and toxicity for PC patients treated with SBRT. Methods: We conducted a retrospective review of patients treated with SBRT using abdominal compression (AC) or an end-expiratory breath-holding (EEBH) technique. The median prescribed dose was 35 Gy, delivered in five fractions. Toxicities were recorded using Common Terminology Criteria for Adverse Events (CTCAE) v5.0, and survival was estimated using the Kaplan–Meier method. Results: From 2017 to 2023, 17 PC patients were offered SBRT. Their median age was 69 years. The median follow-up from the date of diagnosis was 22.37 months. The overall survival (OS) was 94% at 1 year and 60.9% at 2 years. The progression-free survival (PFS) was 63.1% at 6 months and 56.1% at 9 months. The median OS was 26.3 months, and the median PFS was 20.6 months. The 6-month and 1-year LC rates were 71% and 50.8%, respectively. Conclusion: We are successful in implementing the SBRT program at our centre. SBRT appears to be a promising treatment option for achieving LC with limited acute toxicities.